  {"id":1862,"date":"2018-02-13T13:55:24","date_gmt":"2018-02-13T13:55:24","guid":{"rendered":"http:\/\/www.enyopharma.com\/fr\/?p=1862"},"modified":"2018-08-28T08:23:52","modified_gmt":"2018-08-28T08:23:52","slug":"congres-international-sur-les-maladies-du-foie-2018-de-leasl","status":"publish","type":"post","link":"https:\/\/www.enyopharma.com\/fr\/congres-international-sur-les-maladies-du-foie-2018-de-leasl\/","title":{"rendered":"Congr\u00e8s International sur les maladies du foie 2018 de l\u2019EASL"},"content":{"rendered":"<p>Avril 11-15, 2018<\/p>\n<p>Âé¶¹ÆÆ½â°æ est fier d\u2019annoncer que son poster a \u00e9t\u00e9 s\u00e9lectionn\u00e9 pour \u00eatre pr\u00e9sent\u00e9 lors du Congr\u00e8s International sur les maladies du foie de l\u2019EASL se d\u00e9roulant \u00e0 Paris du 11 au 15 Avril. L\u2019\u00e9quipe d\u2019Âé¶¹ÆÆ½â°æ pr\u00e9sentera ses derni\u00e8res \u00e9tudes ainsi que les r\u00e9sultats sur l\u2019H\u00e9patite B de son compos\u00e9 EYP001 (agoniste FXR) d\u00e9velopp\u00e9 pour les patients atteints d\u2019h\u00e9patite B chronique. Le Congr\u00e8s annuel, qui a pour objectif de pr\u00e9senter les derniers sujets de recherche sur les maladies du foie, sera une belle opportunit\u00e9 pour l\u2019entreprise. En effet, plus de 10 000 d\u00e9l\u00e9gu\u00e9s et 250 repr\u00e9sentants de m\u00e9dias venant du monde entier participeront \u00e0 l\u2019\u00e9v\u00e8nement.<a href=\"https:\/\/ilc-congress.eu\/\" target=\"_blank\">(https:\/\/ilc-congress.eu)<\/a><br \/>\n <a href=\"http:\/\/www.enyopharma.com\/wp-content\/uploads\/2018\/04\/Poster-EASL-International-Liver-Congress-2018-ENYO-Pharma.pdf\" rel=\"\" target=\"_blank\" class=\"tano-file\"><span class=\"tano_download_icon\"><\/span><span class=\"tano_file_title\">Poster EASL ILC 2018<\/span><\/a> <\/p>\n<p><img loading=\"lazy\" decoding=\"async\" data-attachment-id=\"1924\" data-permalink=\"https:\/\/www.enyopharma.com\/fr\/congres-international-sur-les-maladies-du-foie-2018-de-leasl\/enyo-pharma-abstract-easl-international-liver-congress-2018\/\" data-orig-file=\"https:\/\/i0.wp.com\/www.enyopharma.com\/wp-content\/uploads\/2018\/02\/ENYO-Pharma-Abstract-EASL-International-Liver-Congress-2018.png?fit=949%2C786&amp;ssl=1\" data-orig-size=\"949,786\" data-comments-opened=\"0\" data-image-meta=\"{&quot;aperture&quot;:&quot;0&quot;,&quot;credit&quot;:&quot;&quot;,&quot;camera&quot;:&quot;&quot;,&quot;caption&quot;:&quot;&quot;,&quot;created_timestamp&quot;:&quot;0&quot;,&quot;copyright&quot;:&quot;&quot;,&quot;focal_length&quot;:&quot;0&quot;,&quot;iso&quot;:&quot;0&quot;,&quot;shutter_speed&quot;:&quot;0&quot;,&quot;title&quot;:&quot;&quot;,&quot;orientation&quot;:&quot;0&quot;}\" data-image-title=\"Âé¶¹ÆÆ½â°æ-Abstract-EASL-International- Liver-Congress-2018\" data-image-description=\"\" data-image-caption=\"\" data-medium-file=\"https:\/\/i0.wp.com\/www.enyopharma.com\/wp-content\/uploads\/2018\/02\/ENYO-Pharma-Abstract-EASL-International-Liver-Congress-2018.png?fit=300%2C248&amp;ssl=1\" data-large-file=\"https:\/\/i0.wp.com\/www.enyopharma.com\/wp-content\/uploads\/2018\/02\/ENYO-Pharma-Abstract-EASL-International-Liver-Congress-2018.png?fit=949%2C786&amp;ssl=1\" src=\"https:\/\/i0.wp.com\/www.enyopharma.com\/wp-content\/uploads\/2018\/02\/ENYO-Pharma-Abstract-EASL-International-Liver-Congress-2018.png?resize=949%2C786\" alt=\"\" width=\"949\" height=\"786\" class=\"alignleft size-full wp-image-1924\" data-recalc-dims=\"1\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Avril 11-15, 2018<\/p>\n<p>Âé¶¹ÆÆ½â°æ est fier d\u2019annoncer que son poster a \u00e9t\u00e9 s\u00e9lectionn\u00e9 pour \u00eatre pr\u00e9sent\u00e9 lors du Congr\u00e8s International sur les maladies du foie de l\u2019EASL se d\u00e9roulant \u00e0 Paris du 11 au 15 Avril. L\u2019\u00e9quipe d\u2019Âé¶¹ÆÆ½â°æ pr\u00e9sentera ses derni\u00e8res \u00e9tudes ainsi que les r\u00e9sultats sur l\u2019H\u00e9patite B de son compos\u00e9 EYP001 (agoniste FXR) d\u00e9velopp\u00e9 pour les patients atteints d\u2019h\u00e9patite B chronique. Le Congr\u00e8s annuel, qui a pour objectif de pr\u00e9senter les derniers sujets de recherche sur les maladies du foie,<\/p>\n<p><a class=\"read-more\" href=\"https:\/\/www.enyopharma.com\/fr\/congres-international-sur-les-maladies-du-foie-2018-de-leasl\/\">Lire la suite&nbsp;&raquo;<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[12],"tags":[],"class_list":["post-1862","post","type-post","status-publish","format-standard","hentry","category-events-fr"],"acf":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","rttpg_featured_image_url":null,"rttpg_author":{"display_name":"editorENYOPharma","author_link":"https:\/\/www.enyopharma.com\/fr\/author\/editorenyopharma\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/www.enyopharma.com\/fr\/category\/events-fr\/\" rel=\"category tag\">\u00c9v\u00e9nements<\/a>","rttpg_excerpt":"Avril 11-15, 2018 Âé¶¹ÆÆ½â°æ est fier d\u2019annoncer que son poster a \u00e9t\u00e9 s\u00e9lectionn\u00e9 pour \u00eatre pr\u00e9sent\u00e9 lors du Congr\u00e8s International sur les maladies du foie de l\u2019EASL se d\u00e9roulant \u00e0 Paris du 11 au 15 Avril. L\u2019\u00e9quipe d\u2019Âé¶¹ÆÆ½â°æ pr\u00e9sentera ses derni\u00e8res \u00e9tudes ainsi que les r\u00e9sultats sur l\u2019H\u00e9patite B de son compos\u00e9 EYP001&hellip;","_links":{"self":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/1862","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/comments?post=1862"}],"version-history":[{"count":10,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/1862\/revisions"}],"predecessor-version":[{"id":2514,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/1862\/revisions\/2514"}],"wp:attachment":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/media?parent=1862"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/categories?post=1862"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/tags?post=1862"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}